Table 1. Characteristics of commercial hepcidin peptides used.
Hepcidin peptide | Commercial source | Product no | Lot number | MW (Da) | pI | Peptide content | Purity |
Heavy hepcidin-25 | PI* | n.a. | 221-006221 | 2829.4† | 8.22 | 100%∧ | >97.8% |
Hepcidin-25 | PI*B | PLP-4392-s | 6103103005438 | 2789.4 | 8.22 | 100%∧68.6% | >98%>95% |
Hepcidin-24 | PI* | n.a. | 740-609191 | 2673.9 | 8.51 | 100%∧ | 96.3% |
Hepcidin-22# | PI | PLP-3776 PI | 001055V | 2436.1 | 8.53 | 74.5% | 96.8% |
Hepcidin-20# | PI | PLP-3777-PI | 001041V | 2191.8 | 8.53 | 67.6% | 96.1% |
catalog product of Peptide International but manufactured by Peptide Institute (Osaka, Japan);
vialed at 100% peptide content;
due to an isotope content of 98% the actual mass is 1 Da less than the theoretical mass of this peptide.
delivered as 0.10 mg per vial; personal communication revealed that ≈ 0.11 mg was pipetted in each vial. PI, Peptide International (Louisville, KY, USA); B, Bachem LTD (St. Helens, UK); n.a., not applicable.